Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats
dc.contributor.author | Ergenoglu A.M. | |
dc.contributor.author | Yeniel A.O. | |
dc.contributor.author | Erbaş O. | |
dc.contributor.author | Aktug H. | |
dc.contributor.author | Yildirim N. | |
dc.contributor.author | Ulukuş M. | |
dc.contributor.author | Taskiran D. | |
dc.date.accessioned | 2019-10-27T08:23:13Z | |
dc.date.available | 2019-10-27T08:23:13Z | |
dc.date.issued | 2013 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | Objective: To evaluate the effect of resveratrol on an experimentally induced endometriosis rat model. Study design: After endometriotic implants were surgically formed, rats were randomly divided into 2 groups as control group (saline treated, n = 6) and resveratrol group (10 mg/kg/d, n = 6). The inflammatory markers and histopathological changes were assessed at the end of the treatment period. Results Our results showed (1) significant reduction in the implant size (P < .0005); (2) significantly decreased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid and plasma (P < .005); and monocyte chemotactic protein 1 (MCP-1) in the peritoneal fluid (P < .05), (3) highly significant suppression of VEGF expression in the endometriotic tissue (P < .0005); and (4) considerable histological changes in the endometriotic foci following resveratrol treatment. Conclusion: Resveratrol appears to be effective on the development of endometriosis through its antiangiogenic and anti-inflammatory properties. Future studies with different doses of resveratrol might provide more comprehensive results regarding the treatment of endometriosis. © The Author(s) 2013. | en_US |
dc.identifier.doi | 10.1177/1933719113483014 | en_US |
dc.identifier.endpage | 1236 | en_US |
dc.identifier.issn | 1933-7191 | |
dc.identifier.issue | 10 | en_US |
dc.identifier.pmid | 23536571 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 1230 | en_US |
dc.identifier.uri | https://doi.org/10.1177/1933719113483014 | |
dc.identifier.uri | https://hdl.handle.net/11454/26390 | |
dc.identifier.volume | 20 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Reproductive Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | cytokines | en_US |
dc.subject | endometriosis | en_US |
dc.subject | MCP-1 | en_US |
dc.subject | resveratrol | en_US |
dc.subject | TNF-? | en_US |
dc.subject | VEGF | en_US |
dc.title | Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats | en_US |
dc.type | Article | en_US |